-
5 Comments
Danaher Corporation is currently in a long term uptrend where the price is trading 17.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.3.
Danaher Corporation's total revenue rose by 138.3% to $7B since the same quarter in the previous year.
Its net income has dropped by 2.7% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 91.7% to $2B since the same quarter in the previous year.
Based on the above factors, Danaher Corporation gets an overall score of 4/5.
![]() |
David Blair
Follow
4 years, 3 months ago
|
![]() |
Matt Rinfield
Follow
4 years, 3 months ago
|
Sector | Healthcare |
---|---|
ISIN | US2358511028 |
Industry | Diagnostics & Research |
Exchange | NYSE |
CurrencyCode | USD |
Target Price | 247.1854 |
---|---|
Beta | 0.9 |
Dividend Yield | 0.6% |
Market Cap | 141B |
PE Ratio | 38.13 |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DHR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025